CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and
CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The
safety and effectiveness of this combination will also be studied. This clinical trial will
be offered to patients who are being considered for treatment with gemcitabine. Research lab
samples and research biopsies will not be requested as part of this study.